Syngene International Limited

“Syngene is a structurally sound India-based CRO/CDMO with a genuine multi-layered moat — client switching costs, regulatory approvals, India cost arbitrage — operating in a large and growing TAM with meaningful China+1 tailwinds. The biologics manufacturing build-out represents a credible long-term value creation runway. However, the current valuation at 35x forward earnings embeds an optimistic recovery scenario that management has already deferred once; with ROE at 6.6%, near-zero FCF, and BMS concentration risk unresolved, the margin of safety is insufficient for a long-term buy. The stock is a TRACK candidate: monitor for a price decline to INR 350-380 where the compounding math becomes genuinely attractive.”